The role of amyloidogenic protein oligomerization in neurodegenerative disease

Journal of Molecular Medicine

Volumn 91, Issue 6, 2013, Pages 653-664

  Lotz, Gregor P ^a   Legleiter, Justin ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloidogenic oligomers; Huntington's disease; Neurodegenerative disease; Parkinson's disease; Therapeutic strategies

Indexed keywords

AMYLOID PROTEIN; CHAPERONE; DIMER; OLIGOMER;

ACTIVE IMMUNIZATION; ANTISENSE THERAPY; CLEARANCE; DEGENERATIVE DISEASE; FIBER; FUNCTIONAL DISEASE; HUMAN; LIPID MEMBRANE; MOLECULAR MECHANICS; NONHUMAN; OLIGOMERIZATION; PASSIVE IMMUNIZATION; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN TARGETING; QUALITY CONTROL; REVIEW; RNA INTERFERENCE; UPREGULATION;

AMYLOIDOGENIC PROTEINS; ANIMALS; HUMANS; MEMBRANE LIPIDS; MOLECULAR CHAPERONES; NEURODEGENERATIVE DISEASES; PROTEIN CONFORMATION; RNA INTERFERENCE;

EID: 84878602267     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1025-1     Document Type: Review

References (151)

1. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annual Review of Biochemistry 333-366
2. Crowther DC (2002) Familial conformational diseases and dementias. Hum Mutat 20:1-14
3. Ross CA, Margolis RL (2005) Neurogenetics: insights into degenerative diseases and approaches to schizophrenia. Clin Neurosci Res 5:3-14
4. Platt GW, Radford SE (2009) Glimpses of the molecular mechanisms of beta(2)-microglobulin fibril formation in vitro: aggregation on a complex energy landscape. FEBS Lett 583:2623-2629
5. Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26:267-298
6. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101-112
7. Kowalewski T, Holtzman DM (1999) In situ atomic force microscopy study of Alzheimer's β-amyloid peptide on different substrates: new insights into mechanism of β-sheet formation. Proc Natl Acad Sci U S A 96:3688-3693
8. Fandrich M (2012) Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. J Mol Biol 421:427-440
9. Broersen K, Rousseau F, Schymkowitz J (2010) The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Alzheimers Res Ther 2:12
10. Sakono M, Zako T (2010) Amyloid oligomers: formation and toxicity of A beta oligomers. FEBS J 277:1348-1358
11. Lashuel HA, Lansbury PT (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 39:167-201
12. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C (2009) Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 284:4230-4237
13. Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc Natl Acad Sci U S A 91:12243-12247
14. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993) Neurodegeneration induced by beta-amyloid peptides in vitro - the role of peptide assembly state. J Neurosci 13:1676-1687
15. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW (1991) In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563:311-314
16. Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J, Albay R, Pensalfini A, Yeung S, Head E et al (2010) Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers. Mol Neurodegner 5:57
17. Okada T, Wakabayashi M, Ikeda K, Matsuzaki K (2007) Formation of toxic fibrils of Alzheimer's amyloid β-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component. J Mol Biol 371:481-489
18. Novitskaya V, Bocharova OV, Bronstein I, Baskakov IV (2006) Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem 281:13828-13836
19. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A (1988) Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 23:138-144
20. Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS (1981) Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 10:184-192
21. Braak H, Braak E (1991) Morphological changes in the human cerebral cortex in dementia. J Hirnforsch 32:277-282
22. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155:853-862
23. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46:860-866
24. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA-J Am Med Assoc 283:1571-1577
25. Tompkins MM, Hill WD (1997) Contribution of somal Lewy bodies to neuronal death. Brain Res 775:24-29
26. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19:2522-2534
27. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ (1999) Huntingtin aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 46:842-849
28. Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66
29. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805-810
30. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, Richards WG, Osmand A, Paganetti P, Bates GP (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington Disease. J Biol Chem 285:8808-8823
31. Lunkes A, Mandel JL (1998) A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet 7:1355-1361
32. Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, D'Ambola J, Hou Z, Liang Y, Poirier MA, Hirschhorn RR, Graham R, Hayden MR, Cole RN, Ross CA (2009) Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem 284:10855-10867
33. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW (2009) Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD Mice. Neuron 64:828-840
34. Mishra R, Hoop CL, Kodali R, Sahoo B, van der Wel PCA, Wetzel R (2012) Serine phosphorylation suppresses huntingtin amyloid accumulation by altering protein aggregation properties. J Mol Biol 424:1-14
35. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, McLean PJ, Young AB, Housman DE, Kazantsev AG (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Nat Acad Sci U S A 103:4246-4251
36. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539
37. Cleary JP, Walsh DM, Hofmeister J, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 8:79-84
38. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL et al (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Nat Acad Sci U S A 95:6448-6453
39. Lesné S, MT K, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-β protein assembly in the brain impairs memory. Nature 440:352-357
40. Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S et al (2012) Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol 7(12):925-934
41. Snell RG, Macmillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, Macdonald ME, Gusella JF, Harper PS, Shaw DJ (1993) Relationship between trinucleotide repeat expansion and phenotypic variation in Huntingtons disease. Nat Genet 4:393-397
42. Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41:689-692
43. Legleiter J, Mitchell E, Lotz GP, Sapp E, Ng C, DiFiglia M, Thompson LM, Muchowski PJ (2010) Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem 285:14777-14790
44. Wetzel R (2012) Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. J Mol Biol 421:466-490
45. Marcellin D, Abramowski D, Young D, Richter J, Weiss A, Marcel A, Maassen J, Kauffmann M, Bibel M, Shimshek DR et al (2012) Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging. PLoS One 7:e44457
46. Olshina MA, Angley LM, Ramdzan YM, Tang JW, Bailey MF, Hill AF, Hatters DM (2010) Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool. J Biol Chem 285:21807-21816
47. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S et al (2011) In vivo demonstration that α-synuclein oligomers are toxic. Proc Nat Acad Sci U S A 108:4194-4199
48. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe C (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489
49. Habicht G, Haupt C, Friedrich RP, Hortschansky P, Sachse C, Meinhardt J, Wieligmann K, Gellermann GP, Brodhun M, Gotz J et al (2007) Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing A beta protofibrils. Proc Nat Acad Sci U S A 104:19232-19237
50. Kodali R, Wetzel R (2007) Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struc Biol 17:48-57
51. Kodali R, Williams AD, Chemuru S, Wetzel R (2010) A beta(1-40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated. J Mol Biol 401:503-517
52. Bauer HH, Aebi U, Haner M, Hermann R, Muller M, Arvinte T, Merkle HP (1995) Architecture and polymorphism of fibrillar supramolecular assemblies produced by in-vitro aggregation of human calcitonin. J Struct Biol 115:1-15
53. Goldsbury CS, Cooper GJS, Goldie KN, Muller SA, Saafi EL, Gruijters WTM, Misur MP (1997) Polymorphic fibrillar assembly of human amylin. J Struct Biol 119:17-27
54. Jimenez JL, Nettleton EJ, Bouchard M, Robinson CV, Dobson CM, Saibil HR (2002) The protofilament structure of insulin amyloid fibrils. Proc Nat Acad Sci U S A 99:9196-9201
55. Bouchard M, Zurdo J, Nettleton EJ, Dobson CM, Robinson CV (2000) Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci 9:1960-1967
56. Dzwolak W, Smirnovas V, Jansen R, Winter R (2004) Insulin forms amyloid in a strain-dependent manner: an FT-IR spectroscopic study. Protein Sci 13:1927-1932
57. Chamberlain AK, MacPhee CE, Zurdo J, Morozova-Roche LA, Hill HAO, Dobson CM, Davis J (2000) Ultrastructural organization of amyloid fibrils by atomic force microscopy. Biophys J 79:3282-3293
58. Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283:29639-29643
59. Chimon S, Shaibat MA, Jones CR, Calero DC, Aizezi B, Ishii Y (2007) Evidence of fibril-like beta-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's beta-amyloid. Nat Struct Mol Biol 14:1157-1164
60. Sandberg A, Luheshi L, Sollvander S, de Barros T, Macao B, Knowles T, Biverstal H, Lendel C, Ekholm-Petterson F, Dubnovitsky A et al (2010) Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. Proc Natl Acad Sci U S A 107:15595-15600
61. Eckert A, Hauptmann S, Scherping I, Meinhardt J, Rhein V, Drose S, Brandt U, Fandrich M, Muller W, Gotz J (2008) Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med-JMM 86:1255-1267
62. Stine WB, Dahlgren KN, Krafft GA, LaDu MJ (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 278:11612-11622
63. Orte A, Birkett NR, Clarke RW, Devlin GL, Dobson CM, Klenerman D (2008) Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. Proc Nat Acad Sci U S A 105:14424-14429
64. Jayaraman M, Kodali R, Sahoo B, Thakur AK, Mayasundari A, Mishra R, Peterson CB, Wetzel R (2012) Slow amyloid nucleation via alpha-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments. J Mol Biol 415:881-899
65. Thakur AK, Jayaraman M, Mishra R, Thakur M, Chellgren VM, Byeon I-JL, Anjum DH, Kodali R, Creamer TP, Conway JF et al (2009) Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol 16:380-389
66. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, Relini A, Stefani M, Dobson C, Cecchi C et al (2010) A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol 6:140-147
67. Glabe CG, Kayed R (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66:S74-S78
68. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey WS (1991) Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 30:7672-7680
69. Pan K-M, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE et al (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 90:10962-10966
70. Bruce ME (2003) TSE strain variation. Brit Med Bull 66:99-108
71. Bessen RA, Marsh RF (1992) Identification of 2 biologically distinct strains of transmissible mink encephalopathy in hamsters. J Gen Virol 73:329-334
72. Bessen RA, Marsh RF (1994) Distinct PrP properties suggest the molecular-basis of strain variation in transmissible mink encephalopathy. J Virol 68:7859-7868
73. Bruce ME (2003) TSE strain variation: an investigation into prion disease diversity. Brit Med Bull 66:99-108
74. González L, Martin S, Begara-McGorum I, Hunter N, Houston F, Simmons M, Jeffrey M (2002) Effects of agent strain and host genotype on PrP accumulation in the brain of sheep naturally and experimentally affected with scrapie. J Comp Pathol 126:17-29
75. Tanaka M, Collins SR, Toyama BH, Weissman JS (2006) The physical basis of how prion conformations determine strain phenotypes. Nature 442:585-589
76. Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC (2000) Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. J Neurosci 20:3606-3611
77. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL et al (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313:1781-1784
78. Stohr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, Prusiner SB, Giles K (2012) Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci U S A 109:11025-11030
79. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M et al (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909-U325
80. Mougenot A-L, Nicot S, Bencsik A, Morignat E, Verchere J, Lakhdar L, Legastelois S, Baron T (2012) Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 33:2225-2228
81. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VMY (2012) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209:975-986
82. Braak H, Del Tredici K (2011) Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol 121:589-595
83. Braak H, Rub U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110:517-536
84. Ravits J, Paul P, Jorg C (2007) Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 68:1571-1575
85. Vonsattel JPG, DiFiglia M (1998) Huntington disease. J Neuropath Exp Neurol 57:369-384
86. Duennwald ML, Shorter J (2010) Countering amyloid polymorphism and drug resistance with minimal drug cocktails. Prion 4:244-251
87. Roberts BE, Duennwald ML, Wang H, Chung C, Lopreiato NP, Sweeny EA, Knight MN, Shorter J (2009) A synergistic small-molecule combination directly eradicates diverse prion strain structures. Nat Chem Biol 5:936-946
88. Stefani M, Dobson CM (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med-JMM 81:678-699
89. Winklhofer KF, Tatzelt J, Haass C (2008) The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 27:336-349
90. Bolognesi B, Kumita JR, Barros TP, Esbjorner EK, Luheshi LM, Crowther DC, Wilson MR, Dobson CM, Favrin G, Yerbury J (2010) ANS binding reveals common features of cytotoxic amyloid species. ACS Chem Biol 5:735-740
91. Balch WE, Morimoto RI, Dillin A, Kelly JW (2008) Adapting proteostasis for disease intervention. Science 319:916-919
92. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292:1552-1555
93. Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI (2006) Progressive disruption of cellular protein folding in models of polyglutaminediseases. Science 311:1471-1474
94. Chen-Plotkin AS, Sadri-Vakill G, Yohrling GJ, Bravernan MW, Berin CL, Glajch KE, DiRocco DP, Farrella LA, Krainc D, Gines S et al (2006) Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiol Dis 22:233-241
95. Hands SL, Wyttenbach A (2010) Neurotoxic protein oligomerisation associated with polyglutamine diseases. Acta Neuropathol 120:419-437
96. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M et al (2004) alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364:1167-1169
97. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106-108
98. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047
99. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R et al (2003) alpha-synuclein locus triplication causes Parkinson's disease. Science 302:841-841
100. Zarranz J, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B et al (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173
101. Charles V, Mezey E, Reddy PH, Dehejia A, Young TA, Polymeropoulos MH, Brownstein MJ, Tagle DA (2000) Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models. Neurosci Lett 289:29-32
102. Fujishiro H, Tsuboi Y, Lin W, Uchikado H, Dickson D (2008) Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol 116:17-24
103. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) beta-Amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 98:12245-12250
104. Olzscha H, Schermann S, Woerner A, Pinkert S, Hecht M, Tartaglia G, Vendruscolo M, Hayer-Hartl M, Hartl F, Vabulas R (2011) Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144:67-78
105. Vabulas R, Hartl F (2011) Aberrant protein interactions in amyloid disease. Cell Cycle 10:1512-1513
106. Calderwood SK, Murshid A, Prince T (2009) The shock of aging: molecular chaperones and the heat shock response in longevity and aging - a mini-review. Gerontology 55:550-558
107. Koga H, Kaushik S, Cuervo AM (2011) Protein homeostasis and aging: the importance of exquisite quality control. Ageing Res Rev 10:205-215
108. Lotz GP, Legleiter J, Aron R, Mitchell EJ, Huang SY, Ng CP, Glabe C, Thompson LM, Muchowski PJ (2010) Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J Biol Chem 285:38183-38193
109. Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6:11-22
110. Chafekar SM, Duennwald ML (2012) Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin. PLoS One 7:e37929
111. Labbadia J, Cunliffe H, Weiss A, Katsyuba E, Sathasivam K, Seredenina T, Woodman B, Moussaoui S, Frentzel S, Luthi-Carter R et al (2011) Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest 121:3306-3319
112. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448:704-U711
113. Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, de Vries R, Arias E, Harris S, Sulzer D et al (2010) Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 13:567-U574
114. Kazlauskaite J, Sanghera N, Sylvester I, Venien-Bryan C, Pinheiro TJT (2003) Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization. Biochemistry 42:3295-3304
115. Legleiter J, Fryer JD, Holtzman DM, Kowalewski T (2011) The modulating effect of mechanical changes in lipid bilayers caused by ApoE-containing lipoproteins on a beta induced membrane disruption. ACS Chem Neurol 2:588-599
116. Porat Y, Kolusheva S, Jelinek R, Gazit E (2003) The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 42:10971-10977
117. Stefani M (2007) Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity. Neuroscientist 13:519-531
118. Yates EA, Cucco EM, Legleiter J (2011) Point mutations in A beta induce polymorphic aggregates at liquid/solid interfaces. ACS Chem Neurol 2:294-307
119. Zhao HX, Tuominen EKJ, Kinnunen PKJ (2004) Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. Biochemistry 43:10302-10307
120. Wells K, Farooqui AA, Liss L, Horrocks LA (1995) Neural membrane phospholipids in Alzheimer disease. Neurochem Res 20:1329-1333
121. Kagan BL, Azimov R, Azimova R (2004) Amyloid peptide channels. J Membr Biol 202:1-10
122. Quist A, Doudevski L, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R (2005) Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Nat Acad Sci U S A 102:10427-10432
123. Yamamoto A, Lucas J, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101:57-66
124. Zu T, Duvick L, Kaytor M, Berlinger M, Zoghbi H, Clark H, Orr H (2004) Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci 24:8853-8861
125. Sah DWY, Aronin N (2011) Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 121:500-507
126. Boudreau RL, McBride JL, Martins I, Shen SH, Xing Y, Carter BJ, Davidson BL (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17:1053-1063
127. Cohen F, Kelly J (2003) Therapeutic approaches to protein-misfolding diseases. Nature 426:905-909
128. Estrada L, Soto C (2006) Inhibition of protein misfolding and aggregation by small rationally-designed peptides. Curr Pharm Des 12:2557-2567
129. De Lorenzi E, Giorgetti S, Grossi S, Merlini G, Caccialanza G, Bellotti V (2004) Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a «protein misfolding disease». Curr Med Chem 11:1065-1084
130. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW (2012) The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 421:185-203
131. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18:64-76
132. Gura T (2008) Hope in Alzheimer's fight emerges from unexpected places. Nat Med 14:894-894
133. de Lartigue J (2012) Tafamidis for transthyretin amyloidosis. Drugs Today 48:331-337
134. Arrasate M, Finkbeiner S (2012) Protein aggregates in Huntington's disease. Exp Neurol 238:1-11
135. Steffan J, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol B, Kazantsev A, Schmidt E, Zhu Y, Greenwald M et al (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-743
136. Iqbal K, Liu F, Gong C, Grundke-Iqbal I (2010) Tau in Alzheimer Disease and related tauopathies. Curr Alzheimer Res 7:656-664
137. Min S, Cho S, Zhou Y, Schroeder S, Haroutunian V, Seeley W, Huang E, Shen Y, Masliah E, Mukherjee C et al (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67:953-966
138. Soga S, Akinaga S, Shiotsu Y (2013) Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Design 19
139. Auluck PK, Meulener MC, Bonini NM (2005) Mechanisms of suppression of alpha-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem 280:2873-2878
140. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M, Sobue G (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11:1088-1095
141. Baldo B, Weiss A, Parker CN, Bibel M, Paganetti P, Kaupmann K (2012) A Screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein. J Biol Chem 287:1406-1414
142. Kalia S, Kalia L, McLean P (2010) Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS Neurol Disord-DR 9:741-753
143. Voisine C, Pedersen J, Morimoto R (2010) Chaperone networks: tipping the balance in protein folding diseases. Neurobiol Dis 40:12-20
144. Hageman J, van Waarde M, Zylicz A, Walerych D, Kampinga HH (2011) The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities. Biochem J 435:127-142
145. Abisambra JF, Jinwal UK, Suntharalingam A, Arulselvam K, Brady S, Cockman M, Jin Y, Zhang B, Dickey CA (2012) DnaJA1 antagonizes constitutive Hsp70-mediated stabilization of tau. J Mol Biol 421:653-661
146. Fewell SW, Smith CM, Lyon MA, Dumitrescu TP, Wipf P, Day BW, Brodsky JL (2004) Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity. J Biol Chem 279:51131-51140
147. Sahara N, Maeda S, Yoshiike Y, Mizoroki T, Yamashita S, Murayama M, Park JM, Saito Y, Murayama S, Takashima A (2007) Molecular chaperone-mediated Tau protein metabolism counteracts the formation of granular Tau oligomers in human brain. J Neurosci Res 85:3098-3108
148. Galimberti D, Scarpini E (2011) Disease-modifying treatments for Alzheimer's disease. Ther Adv Neurol Disord 4:203-216
149. Gerald Z, Ockert W (2013) Alzheimer's disease market: hope deferred. Nat Rev Drug Discov 12:19-20
150. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, Peng K, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W, Wu Y, Tessier-Lavigne M, Watts RJ (2011) A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med 3:84ra43
151. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jonsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488:96-99